Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.09.2023 | Case report

Nivolumab

Anti-transcriptional intermediary factor 1γ antibody-positive dermatomyositis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Sakurai T, et al. Anti-TIF1gammaantibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review. Modern Rheumatology Case Reports 7: 416-421, No. 2, 30 Jan 2023. Available from: URL: http://doi.org/10.1093/mrcr/rxad007 Sakurai T, et al. Anti-TIF1gammaantibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review. Modern Rheumatology Case Reports 7: 416-421, No. 2, 30 Jan 2023. Available from: URL: http://​doi.​org/​10.​1093/​mrcr/​rxad007
Metadaten
Titel
Nivolumab
Anti-transcriptional intermediary factor 1γ antibody-positive dermatomyositis: case report
Publikationsdatum
01.09.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-45660-2

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Pembrolizumab

Case report

Aceclofenac

Case report

Multiple drugs